NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)

RecruitingN/A

Sponsor: AstraZeneca

Conditions: Life Threatening Bleeding, Factor Xa Inhibitor

Countries: Japan

This survey will be conducted to investigate the status of occurrence of the safety specifications set for "Safety specification" in patients who received Ondexxya Intravenous Injection 200 mg. In addition, this survey will be implemented to understand the followings by collecting safety and effectiveness information under actual use conditions.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* All patients treated with this drug to neutralize the anticoagulant effect of a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) at onset of a life-threatening bleeding episode or a unarrestable bleeding episode.

Exclusion Criteria:

* N/A

Locations (61)

Aichi, Japan
Aichi, Japan
Akita, Japan
Aomori, Japan
Chiba, Japan
Chiba, Japan
Ehime, Japan
Ehime, Japan
Fukui, Japan
Fukui, Japan
Fukuoka, Japan
Fukuoka, Japan
Fukushima, Japan
Gifu, Japan
Gifu, Japan
Gunma, Japan
Gunma, Japan
Gunma, Japan
Hiroshima, Japan
Hokkaido, Japan
Hokkaido, Japan
Hyōgo, Japan
Ibaraki, Japan
Ishikawa, Japan
Kagawa, Japan
Kagoshima, Japan
Kanagawa, Japan
Kochi, Japan
Kumamoto, Japan
Kumamoto, Japan
+ 31 more on CT.gov